CRVS
NASDAQ
US
Corvus Pharmaceuticals, Inc. - Common Stock
$14.69
▲ +$0.26
(+1.80%)
Vol 660K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$575.1M
ROE
-25.8%
D/E
0.00
Beta
0.73
52W
$3–$10
Wall Street Consensus
13 analysts · Apr 20265
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
92.3%
Buy Rating
Price Chart
Similar Stocks
OLMA
Olema Pharmaceuticals Inc
$2.0B
ZBIO
Zenas Biopharma Inc
$2.3B
TSHA
Taysha Gene Therapies Inc
$1.5B
NVAX
Novavax Inc
P/E 3.2
$1.1B
SVRA
Savara Inc
$1.2B
AVBP
ArriVent BioPharma Inc
$830.6M
GERN
Geron Corp
$842.6M
KALV
Kalvista Pharmaceuticals Inc
$816.3M
CTMX
CytomX Therapeutics Inc
P/E 25.8
$721.8M
Earnings
Beat rate: 75.0%
Next Report
May 06, 2026
EPS Estimate: $-0.15
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.15 | — | — |
| Dec 2025 | $-0.13 | $-0.15 | $-0.02 |
| Sep 2025 | $-0.14 | $-0.12 | +$0.02 |
| Jun 2025 | $-0.14 | $-0.10 | +$0.04 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -103.4% | -103.4% | -103.4% | -103.4% | -25.8% | -25.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 8.91 | 8.91 | 8.91 | 8.91 | 8.29 | 8.29 |
Key Ratios
ROA (TTM)
-20.2%
P/B
10.6
EPS (TTM)
$-0.20
CF/Share
$-0.63
52W High
$9.60
52W Low
$2.54
$2.54
52-Week Range
$9.60
How does CRVS compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CRVS valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
10.6
▲
329%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CRVS profitability vs Biotechnology peers
ROE
-25.8%
▲
62%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-20.2%
▲
57%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
CRVS financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
8.3
▲
87%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.7
▼
25%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
CRVS fundamentals radar
CRVS
Peer median
Industry
CRVS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CRVS vs peers: key metrics
Latest News
No related news yet